Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProKidney Corp.

ProKidney Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.12 USD 0.05 ( 4.67%)
Last update at 2026-11-04T21:00:00Z
VOLUME
1108337
Market Cap
1816.72M

Momentum Score

…

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.01
Low
1.14
High
52 Week Price Range
1.12
Low
13.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.07
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.00
ROE
-31.72%
Net Debt
-56.24M
ROCE
-38.69%
Diluted EPS TTM
-0.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -147.24M -55.11M -26.98M -
Minority interest 40.10M - - -
Net income -148.13M -55.15M -26.75M -
Selling general administrative 70.94M 8.86M 5.98M -
Reconciled depreciation 3.04M 1.98M 0.96M -
Ebit -153.01M -55.11M -27.02M -19.16M
Ebitda -143.99M -53.13M -26.02M -
Depreciation and amortization 9.02M 1.98M 1.01M -
Non operating income net other 5.98M - - -
Operating income -153.01M -55.11M -27.02M -
Other operating expenses 153.01M 55.11M 27.02M -
Interest expense 0.21M 0.00M 0.04M 0.00M
Tax provision 0.90M 0.04M -0.23M -
Interest income 5.98M 0.00M 0.04M -
Net interest income 5.77M 0.00M 0.04M -
Income tax expense 0.90M 0.04M -0.23M 0.36M
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 153.01M 55.11M 27.02M -
Total other income expense net 5.77M 0.00M 0.04M -
Net income from continuing ops -148.13M -55.15M -26.75M -
Net income applicable to common shares -188.24M -55.15M -26.75M -79.61M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 420.55M 518.00M 40.30M 16.70M -
Intangible assets - 0.21M - - -
Other current assets 9.82M 1.38M 0.03M 0.05M -
Total liab 29.22M 13.06M 13.38M 6.84M -
Total stockholder equity -1103.40M -1096.62M 26.92M 9.86M -
Other current liab 22.76M 7.34M 9.21M 4.50M 0.35M
Common stock 0.02M 0.02M 188.43M 116.23M 95.50M
Capital stock 0.02M 0.02M 188.43M 116.23M -
Retained earnings -1139.66M -1104.12M -161.51M -106.36M -79.61M
Cash 60.65M 490.25M 20.56M 4.58M -
Total current liabilities 25.04M 10.87M 12.31M 5.50M 2.71M
Current deferred revenue -3.63M - - - -
Net debt -56.24M -487.85M -19.22M -3.02M -
Short term debt 0.80M 0.49M 0.27M 0.23M -
Short long term debt total 4.41M 2.40M 1.33M 1.56M -
Other stockholder equity 36.11M 7.48M 249.76M - -
Property plant equipment - 10.71M 12.60M 10.47M 3.33M
Total current assets 374.15M 504.72M 27.27M 5.58M 15.42M
Net tangible assets - 504.94M 26.49M 9.22M 15.03M
Short term investments 302.30M - - - -
Net receivables 1.38M - - - -
Accounts payable 5.10M 3.04M 2.83M 0.78M 0.48M
Accumulated other comprehensive income 0.13M - - - -
Common stock total equity - 0.02M - - -
Retained earnings total equity - -1104.12M - - -
Non current assets total 46.41M 13.28M 13.03M 11.12M -
Capital lease obligations 4.41M 2.40M 1.33M 1.56M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.74M -5.19M -5.46M -
Change to liabilities 0.77M 7.87M 0.68M 1.20M
Total cashflows from investing activities -1.74M -5.19M -5.46M -2.97M
Net borrowings - -0.03M -0.01M -0.01M
Total cash from financing activities 548.52M 71.47M 19.99M 20.00M
Change to operating activities -7.23M -5.70M -0.81M -0.12M
Net income -148.13M -55.15M -26.75M -79.61M
Change in cash 469.69M 15.98M -10.65M -59.77M
Begin period cash flow 20.56M 4.58M 15.23M -
End period cash flow 490.25M 20.56M 4.58M 15.23M
Total cash from operating activities -77.09M -50.30M -25.18M -76.81M
Depreciation 3.04M 1.98M 0.96M 0.87M
Other cashflows from investing activities 0.11M 0.11M 0.11M 0.11M
Sale purchase of stock 542.50M - - -
Other cashflows from financing activities 583.55M 71.50M 20.00M 542.50M
Change to netincome 74.47M 0.70M 0.73M 0.50M
Capital expenditures 1.85M 5.19M 5.46M 1.30M
Cash flows other operating -7.23M - - -
Cash and cash equivalents changes 469.69M - - -
Change in working capital -6.46M 2.16M -0.13M -
Stock based compensation 74.47M 0.70M 0.73M -
Free cash flow -78.94M -55.49M -30.64M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PROK
ProKidney Corp.		 0.05
4.67%		 1.12 - - - 91.32 1.99
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103

336 999 7028

https://www.prokidney.com

163

Name Title Year Born
Dr. Timothy A. Bertram D.V.M., Ph.D. Founder, CEO & Director 1955
Mr. James Coulston CPA Chief Financial Officer 1976
Dr. Deepak Jain Ph.D. Chief Operating Officer 1954
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. Sr. VP of Investor Relations NA
Mr. Todd C. Girolamo Esq., J.D., M.B.A. Chief Legal Officer & Corp. Sec. 1965
Dr. Libbie P. McKenzie M.D. Chief Medical Officer 1973
Ms. Ashley H. Johns Sr. VP of Clinical Operations NA
Dr. Joseph M. Stavas M.D. Sr. VP of Clinical Devel. NA
Dr. Darin J. Weber Ph.D. Sr. VP of Regulatory Devel. 1968
Dr. Kerry Cooper M.D. Sr. VP of Medical Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…